#1JANUARY 10, 2024 JP Morgan Healthcare Conference Innovation Update David Endicott Chief Executive Officer Alcon PAGE 1 BUSINESS USE ONLY#2Safe Harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our liquidity, revenue, gross margin, operating margin, effective tax rate, foreign currency exchange movements, earnings per share, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our transformation program, market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance. PAGE 2 Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches or other disruptions of our information technology systems; compliance with data privacy, identity protection and information security laws; our ability to comply with the US Foreign Corrupt Practices Act of 1977 and other applicable anti-corruption laws, particularly given that we have entered into a three-year Deferred Prosecution Agreement with the US Department of Justice; the impact of a disruption in our global supply chain or important facilities, including our reliance on single source suppliers; supply constraints and increases in the cost of energy; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our customers; our ability to manage environmental, social and governance matters to the satisfaction of our many stakeholders, some of which may have competing interests; our success in completing and integrating strategic acquisitions; the success of our research and development efforts, including our ability to innovate to compete effectively; global and regional economic, financial, legal, tax, political and social change; our ability to comply with all laws to which we may be subject; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to properly educate and train healthcare providers on our products; our reliance on outsourcing key business functions; our ability to attract and retain qualified personnel; the impact of unauthorized importation of our products from countries with lower prices to countries with higher prices; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; our ability to protect our intellectual property; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; effect of product recalls or voluntary market withdrawals; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to a US corporation; and the effect of maintaining or losing our foreign private issuer status under U.S. securities laws. Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this document speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. Intellectual property This presentation may contain references to our proprietary intellectual property. All product names appearing in italics or followed by Ⓡ or TM symbols are trademarks owned by or licensed to Alcon Inc. Non-IFRS measures Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currencies and free cash flow. Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These non-IFRS measures are presented solely to permit investors to more fully understand how Alcon management assesses underlying performance. These non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures. Alcon BUSINESS USE ONLY#3JP MORGAN HEALTHCARE CONFERENCE | INNOVATION UPDATE MARKETS & STRATEGY Alcon PAGE 3 BUSINESS USE ONLY#4DURABLE, RESILIENT MARKETS BROAD PORTFOLIO IN RESILIENT MARKETS GROWING AT MID-SINGLE DIGITS TOTAL MARKET SURGICAL VISION CARE Alcon IMPLANTABLES² CONSUMABLES² EQUIPMENT / OTHER² CONTACT LENSES 2023 INDUSTRY SALES¹ ($B) OCULAR HEALTH² -$10 $11 $3 $6 $4 $33B $13B CAGR: -5% $21B CAGR: -4% 2023-2028E INDUSTRY CAGR¹ Note: Combined standalone market sizes may not add up to total market size due to rounding 1. Market Scope, GfK, Nielsen, IQVIA, Euromonitor, Alcon internal Estimates, see Safe harbor statement for more information about future industry growth projections; 2. Implantables include IOLS, surgical glaucoma devices; Consumables include cataract, vitreoretinal, and refractive disposable instruments; Equipment / other includes cataract and vitreoretinal consoles and accessories, FLACS lasers, refractive lasers, equipment service & maintenance, microscopes, diagnostics, and drops for mydriatics, cycloplegics, diagnostics and anaesthetics; Ocular Health includes artificial tears, allergy, contact lens care, rewetting drops, redness relievers, dry eye devices, general eye care and other categories, as well as glaucoma Rx drops. 4-5% -6% ~5% -6% PAGE 4 ~5% -2% BUSINESS USE ONLY#5GROWTH SUMMARY ALCON GROWTH ACCELERATED ACROSS CATEGORIES IN RECENT YEARS FROM INNOVATION WAVE ALC CATEGORY GROWTH VS. PRIOR YEAR IN RECENT YEARS Full Year cc growth vs. the prior year, except 2021 which is compared to 2019 Ocular Health Contact Lenses Equipment Impantables Consumables Alcon $6.6B 2016 (+3%) $6.8B 2017 (+5%) $7.1B 2018 (+5%) $7.4B 2019 +12% Note: Year 2020 excluded from the chart due to market anomaly during COVD 1. US launch of Acrysof Pan Optix $8.2B 2021 +11% $8.7B 2022 9m YTD +11% 2023 PAGE 5 • Growth increased from in line with market 3-5% to double digit, well exceeding market • Inflection driven by launches of PanOptix¹ and Precision1, followed up by launches of Vivity and Pataday ● Wave of innovation continues with Total30 and Precision7, Clareon PanOptix / Vivity and upcoming Unity equipment launches BUSINESS USE ONLY#6STRATEGY ALCON STRATEGY WE FOCUS ON EYE CARE We create value by applying specialty market and technical knowledge to create products that improve sight Alcon ST? Specialty market expertise • Data driven customer insights • Market assessment Market access & development • Global commercialization ● Specialty technology expertise Optical design and engineering Clinical endpoints and trial design Formulations and drug delivery • Software engineering and digital technologies ● Disciplined management Efficient enabling functions • Leverage digital enterprise ● • Efficient search & development • Disciplined capital deployment PAGE 6 ● BUSINESS USE ONLY#7JP MORGAN HEALTHCARE CONFERENCE | INNOVATION UPDATE VISION CARE INNOVATION Alcon PAGE 7 BUSINESS USE ONLY#8VISION CARE INNOVATION SIGNIFICANT VISION CARE PRODUCT FLOW SINCE SPIN Alcon 2019-2020 PRECISION 1 ND > Pataday. Twice Daily and Once Daily (US) PRECISION 1 for Astigmatism TOTAL 30 ONE MONTH REPLACEMENT CONTACT LENSES 2021-2023 ONCE-DAILY Pataday. Once Daily Extra Strength (US) TOTAL 30 ONE MONTH REPLACEMENT CONTACT LENSES SIMBRINZAⓇ DAILIES for Astigmatism TOTAL 1 rocklatan) TOTAL 30 ONE MONTH REPLACEMENT CONTACT LENSES Multifocal ASTIGMATISM Systane LUBRICANT EYE DROPS Complete, Ultra and Hydration MDPF EYSUVIS rhopressa Alcon PRECISION 7 ONE WEEK CONTACTLENSES PRESERVATIVE FREE ALL-IN-ONE Dry Eye Relief For all types of irstated, dry eye Alcon COMPLETE LUBRICANT ENE DROPS Alcon Vico + HA 2024-2026 AR-15512 (DRY EYE DISEASE, PENDING PHASE 3 CLINICALS) STERSE A List is not exhaustive. New product launches may not be listed in chronological order. See Safe harbor statement and the assumptions underlying our outlook for more information; Systane nano-lipids + Hyaluronic Acis image is concept image and not final PRECISION 7 ONE WEEK CONTACT LENSES Alcon Vico for Astigmatism TOTAL 30 ONE-MONTH REPLACEMENT CONTACT LENSES Multifocal Toric € PAGE 8 BUSINESS USE ONLY#9VISION CARE INNOVATION DOUBLE DIGIT SYSTANE MDPF GROWTH FUELED STRONG OCULAR HEALTH GAINS New Formla Systane Systane LUBRICANT FYE DROPS LUBRICANT EYEDOOPS PRESERVATIVE-FREE ALL-IN-ONE Dry Eye Relief For all types of irritated, dry eye 10mL Alcon STERILE & Systane HYDRATION HURRICANT EYE CROPS PRESERVATIVE FREE LONG-LASTING Diry Eye Relief Contains Hyaluronic-acid for advanced hydration 10mil Alcon STOLA Alcon PRESERVATIVE-FREE FAST-ACTING Dry Eye Relief For High Performance 10ml. Alcon 'I Doctor Recommended Brand OCULAR HEALTH GROWTH STERLE Systane ULTRA EXTENDED PROTECTION FAST SYMPTOM RELIEF PRESERVATIVE-FREE VIALS STERILE CONVENT PRESERVERE VIALS LUBRICANT EYE DROPS HIGH PERFORMANCE 25 Vials 0.7 mL Each Alcon Rx 2% OTC 10% 2021 1% 6% 2022 10% 10% Q3 2023 NEW COMBINED STRENGTH OF SYSTANE COMPLETE PLUS HYALURONIC ACID FOR LONGER RELIEF Www Formula COMPLETE LUBRICANT EYE DROPS LIN canclagy PRESERVATIVE-FREE ALL-IN-ONE Dry Eye Relief For all types of irritated, dry eye 10mL Alcon TM STERILE A Hyaluronic Acid (HA) Strong Market Interest¹ Doctor intent to recommend PAGE 9 Consumer intent to purchase Note: Systane Complete + Hyaluronic Acid image is concept image and not final 1. Represents the percentage of US dry eye consumers and eye care practitioners who indicated they "definitely" or "probably would" (the two strongest choices) intend to purchase or recommend, respectively, in an Alcon concept research study conducted in Q4 2022 Source: Alcon internal data (+) 86% 81% BUSINESS USE ONLY#10VISION CARE INNOVATION CONTACT LENS: RECENT INNOVATIONS IN DAILIES AND REUSABLES ARE WINNING IN THE MARKET ALC GLOBAL CONTACT LENS MARKET SHARE EVOLUTION¹ ~260 basis points of share growth² 1 POINT OF SHARE GROWTH = ~$100M IN ALC REVENUE³ DT1 MF US and INT launch Alcon P1 Sph US launch 24 DT1 Tor. US launch 24 25 25 -26%² T30 EU launch T30 US launch P1 Sph/Tor INT launch P1 Toric US launch Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 -16 -16 -16 -16 -17 -17 -17 -17 -18 -18 -18 -18 -19 -19 -19 -19 -20 -20 -20 -20 -21 -21 -21 -21 -22 -22 -22 -22 -23 -23 -23 ALC CL REVENUE GROWTH VS. PRIOR YEARS 2% 2016 4% 4% 4% 2017 2018 1. Source: GfK Market Intelligence: growth rate Q3 2022 vs Q3 2019 in sales value for panel in US, JP, KR, SG, MY, CH, DE, ES, DK, FR, GB, IT, NO, PL, RU, SE. Excludes China. Note that panel market coverage may vary over time. 2. Source: GfK Market Intelligence; brand share based on sales value in Q1 2011 and Q1 2023 for panel markets in same countries as in 1. 3. Source: Internal Calculations 7% 2019 2021 vs. I 2019 PAGE 10 9% 2022 11% 2023 9m YTD BUSINESS USE ONLY#11VISION CARE INNOVATION ROCKLATAN TOTAL PRESCRIPTIONS (TRX) HAVE BEEN PERFORMING WELL MONTHLY TRX - ROCKLATAN 32 30 28 26 24 22 20 18 16 14 12 10 TOTAL PRESCRIPTIONS (000s) Jan 2021 Alcon мини June 2022 Usual dosage One drop in the affected evels) once caly in the evening Store at 20-8°C 36-46%) During shipment, the bottle may be maintained at temperatures up to 40C104FF) for a period not exceeding 14 days. After opening Rockatan can be used until the expiration date on the botte PROTECT FROM LIGHT NDC 70727-529-25 rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%0.005% For topical application in the eye Sterile Rx only 2.5 mL Nov 2023 Tria 23-529-15 rocklatan Intorsudil and latenoprest amit solution) 0.020005 2.5 mL Rxonly ● ● ● PAGE 11 Q3 2023 YTD Unit Growth and Share gains (TRX +8% vs. PY, Market +1.5%) Aerie integration complete and sales force trained and aligned Expanding Pharma with new pipeline assets Note: Sub-national data used for territory-level reporting that does not include non-projected mail order data; This information is an estimate derived from the use of information under license from the following IQVIA information service: Xponent PlanTrak: HCP/Plan subnational level for the period Jan 2021 - Nov 2023. IQVIA expressly reserves all rights, including rights of copying, distribution and republication Source: IQVIA BUSINESS USE ONLY#12VISION CARE INNOVATION COMET-2: PROPORTION WITH ≥10 mm INCREASE IN SCHIRMER SCORE AR-15512: PRIMARY ENDPOINT MET IN BOTH COMET STUDIES, SUPPORTING PATH TO SEEK FULL INDICATION OF TREATMENT OF SIGNS AND SYMPTOMS OF DED¹ Proportion of Subjects 60%- 40%- 20%- *p<0.0001 ilill LLL Day 28 0%- 60%- 40%- 20% 0% *p<0.0001 Day 1 Alcon *p<0.0001 Day 14 Study Visit COMET-3: PROPORTION WITH ≥10 mm INCREASE IN SCHIRMER SCORE *p<0.0001 Day 7 Day 1 *p<0.0001 *p<0.0001 *p<0.0001 LLLLL Day 7 Day 14 Study Visit *p<0.0001 *p<0.0001 Day 90 Day 28 *p<0.0001 AR-15512 Vehicle Primary Endpoint Day 90 AR-15512 is an investigational product and has not been submitted to US FDA for approval AR-15512 Vehicle Primary Endpoint NDA FILING PLANNED FOR MID-YEAR '24 2023 COMET 2 COMET 3 1. Efficacy requirement for full indication of treatment of signs and symptoms of Dry Eye Disease met in accordance with FDA 2020 draft guidance for Dry Eye. 2024 PAGE 12 COMET 4 Phase 3: Safety Study (on track) NDA filing BUSINESS USE ONLY#13VISION CARE INNOVATION AR-15512: DIFFERENTIATED PRODUCT CANDIDATE WITH THE OPPORTUNITY TO WIN SHARE IN THE ~$1.4B U.S. MARKET¹ DRY EYE DISEASE OPPORTUNITY³3 Alcon 38M US POPULATION W/ DED 18M DIAGNOSED W/ DED <1.6M Treated with Rx Less than 10% of diagnosed DED patients are treated with an Rx product, leaving significant opportunity to grow the category ● ● AR-15512 is an investigational product and has not been submitted to US FDA for approval ● AR-15512 PAGE 13 First-in-class product candidate for the treatment of the signs & symptoms of Dry Eye Disease TRPM8 Agonist: Rapidly stimulates the production of natural tears (primary endpoint - Day 14 efficacy) Effective as early as Day 1 and persistent to Day 90 (secondary endpoints) with the potential to address the limitations of current Rx options Estimated peak sales: $250M - 400M² 1. Does not include OTC artificial tears and tear stimulants; 2. Represents a current estimate of the potential peak sales range AR-15512 could achieve assuming approval by relevant regulatory authorities. AR-15512 is an investigational product: Not yet submitted to U.S. FDA for approval; 3. Source: Market Scope 2023 Dry Eye Products Market Report BUSINESS USE ONLY#14JP MORGAN HEALTHCARE CONFERENCE | INNOVATION UPDATE SURGICAL INNOVATION Alcon PAGE 14 BUSINESS USE ONLY